行情

KZIA

KZIA

Kazia
NASDAQ

实时行情|Nasdaq Last Sale

3.215
-0.302
-8.59%
已收盘, 16:00 11/19 EST
开盘
3.590
昨收
3.517
最高
3.600
最低
3.215
成交量
1.12万
成交额
--
52周最高
4.270
52周最低
2.110
市值
1,998.78万
市盈率(TTM)
-2.5839
分时
5日
1月
3月
1年
5年

EPS

KZIA 新闻

  • 沪指低开低走 纽约联储主席称美经济面临下行风险
  • 新浪财经.1小时前
  • 谷歌Android系统再曝漏洞 恶意应用可以秘密录制视频
  • 36氪.4小时前
  • 气势如虹!科技股有望迎来2009年以来表现最佳之年
  • 环球外汇网官网.5小时前
  • 击败亚马逊微软 谷歌赢得沃达丰数据服务大单
  • TechWeb.5小时前

更多

所属板块

生物技术和医学研究
+2.16%
制药与医学研究
+0.78%

热门股票

名称
价格
涨跌幅

KZIA 简况

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
展开

Webull提供Kazia Therapeutics Ltd (ADR)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。